Loading provider…
Loading provider…
Hematology & Oncology Physician in New York, NY
NPI: 1255332839Primary Practice Location
NEW YORK-PRESBYTERIAN HOSPITAL
5141 Broadway, New York, NY
Primary Employer
Weill Medical College of Cornell
med.cornell.edu
HQ Phone
Get DO Anna's Phone Numberphone_androidMobile
Get DO Anna's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License

NJ State License
Current

NY State License
1991 - 2027

American Board of Internal Medicine
Medical Oncology
Memorial Sloan Kettering Cancer Center
Fellowship • Hematology and Medical Oncology
1993 - 1996
Hackensack University Medical Center
Residency • Internal Medicine
1990 - 1993
Rowan-Virtua School of Osteopathic Medicine - Stratford
som.rowan.edu
Medical School
Until 1990
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 150 | 417 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 83 | 144 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 44 | 44 |
| 4 | 96413Infusion of chemotherapy into a vein up to 1 hour | 38 | 187 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 23 | 28 |
Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma
Authors: Anuj Bapodra, Russell Berman, Nathaniel Fleming
Journal: J Med Genet
Publication Date: 2015-01-20
Innovations in the treatment of melanoma.
Authors: Anna C. Pavlick
Publication Date: 2004-09
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
Authors: Anna C. Pavlick, Jennifer Wu, John D. Roberts, Mark A. Rosenthal, Anne Hamilton, Scott Wadler, K. Farrell, Michelle Carr, D. Fry, Anthony J. Murgo, Ruth Oratz, Howard S. Hochster, Leonard Liebes, Franco M. Muggia
Publication Date: 2009-02
Lead Sponsor: Replimune Inc.
Collaborators: Bristol-Myers Squibb
Intervention / Treatment: BIOLOGICAL: RP1, BIOLOGICAL: nivolumab
Lead Sponsor: Nina Bhardwaj
Collaborators: Oncovir, Inc., NYU Langone Health, Memorial Sloan Kettering Cancer Center, Melanoma Research Alliance, Ludwig Institute for Cancer Research
Intervention / Treatment: BIOLOGICAL: Poly-ICLC, BIOLOGICAL: DC Vaccine, BIOLOGICAL: Montanide Vaccine
Lead Sponsor: Celldex Therapeutics
Intervention / Treatment: DRUG: glembatumumab vedotin, DRUG: glembatumumab vedotin and varlilumab, DRUG: glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab), DRUG: glembatumumab vedotin and CDX-301